Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; magnesium stearate - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: povidone; colloidal anhydrous silica; magnesium stearate - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

United States - English - NLM (National Library of Medicine)

amol pharmaceuticals private limited - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - methenamine 162 mg

United States - English - NLM (National Library of Medicine)

method pharmaceuticals, llc - methenamine mandelate (unii: 695n30cinr) (methenamine - unii:j50oix95qv) - methenamine mandelate, usp is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. when used as recommended, methenamine mandelate, usp is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. pathogens resistant to other antibacterial agents may respond to methenamine mandelate, usp because of the nonspecific effect of formaldehyde formed in an acid urine. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine mandelate, usp and other antibacterial drugs, methenamine mandelate, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. prophylactic use rationale:  urine is a good culture medium for many urinary pathogens. inocul

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - methenamine mandelate (unii: 695n30cinr) (methenamine - unii:j50oix95qv) - methenamine mandelate is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. when used as recommended, methenamine mandelate is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop.  pathogens resistant to other antibacterial agents may respond to methenamine mandelate because of the nonspecific effect of formaldehyde formed in an acid urine. prophylactic use rationale: urine is a good culture medium for many urinary pathogens. inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. there is a growing body of evidence that lon

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - methenamine mandelate (unii: 695n30cinr) (methenamine - unii:j50oix95qv) - methenamine mandelate, usp is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. when used as recommended, methenamine mandelate, usp is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. pathogens resistant to other antibacterial agents may respond to methenamine mandelate, usp because of the nonspecific effect of formaldehyde formed in an acid urine. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine mandelate, usp and other antibacterial drugs, methenamine mandelate, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. prophylactic use rationale:  urine is a good culture medium for many urinary pathogens. inocul

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - methenamine mandelate (unii: 695n30cinr) (methenamine - unii:j50oix95qv) - methenamine mandelate is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. when used as recommended, methenamine mandelate is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. pathogens resistant to other antibacterial agents may respond to methenamine mandelate because of the nonspecific effect of formaldehyde formed in an acid urine. prophylactic use rationale:  urine is a good culture medium for many urinary pathogens. inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. there is a growing body of evidence that long-te

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - methenamine hippurate - oral tablet - 1gram